newsfilter
← Earnings
Earnings Releases·

Silexion Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss decreased 24.2% year-over-year to $2.5 million for Q3 2026, though the nine-month loss widened 17.3% to $8.8 million; R&D expenses dropped 40.9% in Q3 but rose 28.9% for the nine-month period due to the Phase 2/3 trial ramp-up.
  • SIL204 entered active patient treatment with the first dose in the Phase 2/3 trial for KRAS-mutant pancreatic cancer on September 30, 2026, with plans to enroll the first patient group and expand site activation in Israel and Germany.
  • Cash and cash equivalents stood at $4.8 million as of September 30, 2026, following $5.24 million in total capital raised during the quarter via public offering, warrant inducement, and at-the-market sales.
  • The Company faces substantial doubt regarding its ability to continue as a going concern and must maintain compliance with Nasdaq listing requirements for shareholders' equity and minimum bid price.
  • A 1-for-24 reverse share split was effected on November 10, 2026, following a prior 1-for-10 split in May 2026, while trade payables increased to $1.2 million and the Related Party Promissory Note was reduced to $0.
Company
SILEXION THERAPEUTICS CORP
Sector
Healthcare
Industry
Biotechnology